The department of Health and Human Services has placed therapeutic monoclonal antibodies (i.e. REGEN-COV, bamlanivimab/etesevimab) for COVID-19 treatment on state-administered allocation.
The Ohio Department of Health will allocate weekly supply to hospitals and health systems based on case count and supply availability. Kettering Health is constantly reviewing restrictions of COVID-19 treatments based on supply chain considerations, patient volume, and current literature.
Based on estimated allocation, current usage, and provider feedback, the Kettering Health Pharmacy and Therapeutics Committee has approved changes to the COVID-19 monoclonal antibody (mAb) restrictions for both hospital and infusion center use.
Below is a summary of changes:
- “Not fully vaccinated” removed as a post-exposure prophylaxis (PEP) qualifier (to align with treatment criteria)
- Verbiage change to Treatment Referral Forms for improved clarity
- No changes in treatment use criteria
Changes to EPIC referral forms and order panels will be updated throughout the day. Updated paper copies of the referral forms are here for your reference. Please see attached order forms for complete list of requirements for COVID-19 monoclonal antibody use.
*Note: Infusion Center patients must be 18 years or older. Patients treated through the ED or as inpatients must be 16 years or older.
We will continue to reevaluate this decision at regular intervals and provide updates to these restrictions as appropriate.